Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication BioSpaceBioMarin's discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.Rare DiseaseRead full story pharminent August 10, 2026 (Last updated: August 11, 2026) BioSpace BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Replimune Readies Launch of Newly Approved Melanoma Therapy TudriqevNext: Jazz Pharmaceuticals Acquires Actio Biosciences for $820M Upfront Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026 Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026
